With respect to prescription drugs, we are working to make sure that the information that's contained, both for physicians and for consumers, is significantly easier to read. So we're introducing a series of steps. By means of these, the prescribers can make sure they have the information to determine the appropriate course of action for the patient. They know when to use it and when not to use it. They will know the potential side effects so they can make an informed choice. We're also working to make sure that this information is easier for consumers to understand, so they can participate in a dialogue with their physicians.
In addition, as the minister said, we're looking to make summaries of our drug safety reviews available. We hope to have the first one later this fiscal year. That's an important step in furthering transparency.